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ABSTRACT
Introduction: There is a lack of agreed and
established guidelines for the treatment of acute
exacerbations of idiopathic pulmonary fibrosis
(AE-IPF). This reflects, in part, the limited
evidence-base underpinning the management
of AE-IPF. In the absence of high-quality
evidence, the aim of this research was to
develop a clinician-led consensus statement
for the definition, diagnosis and treatment of
AE-IPF.
Methods: A literature review was conducted to
obtain published material on the definition and
treatment of AE-IPF. The results of this review
were circulated to an online panel of clinicians
for review. Statements were then shared with
ten expert respiratory clinicians who regularly
treat patients with IPF. A Delphi technique was
then used to develop a consensus statement for
the definition, diagnosis and treatment of
AE-IPF. During the first round of review,
clinicians rated the clarity of each statement,
the extent to which the statement should be
included and provided comments. In two
subsequent rounds of review, clinicians were
provided with the group median inclusion
rating for each statement, and any revised
wording of statements to aid clarity. Clinicians
were asked to repeat the clarity and inclusion
ratings for the revised statements.
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Results: The literature review, online panel
discussion, and face-to-face meeting generated
65 statements covering the definition,
diagnosis, and management of AE-IPF.
Following three rounds of blind review, 90%
of clinicians agreed 39 final statements. These
final statements included a definition of AE-IPF,
approach to diagnosis, and treatment options,
specifically: supportive measures, use of
anti-microbials, immunosuppressants,
anti-coagulants, anti-fibrotic therapy,
escalation, transplant management, and
long-term management including discharge
planning.
Conclusion: This clinician-led consensus
statement establishes the ‘best practice’ for the
management and treatment of AE-IPF based on
current knowledge, evidence, and available
treatments.
Funding: Boehringer Ingelheim Ltd., Bracknell,
West Berkshire, UK.
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INTRODUCTION
The most common form of idiopathic
interstitial pneumonia (IIP) is idiopathic
pulmonary fibrosis (IPF) [1, 2], accounting for
almost 25% of all interstitial lung diseases (ILD)
[3, 4]. IPF is a chronic, progressive, and
irreversible life-limiting condition. Prognosis is
poor, with many patients surviving less than
3–5 years following diagnosis [5–7]. IPF is
typically characterized clinically by progressive
dyspnea with worsening respiratory status [1,
2], resulting in progressive functional limitation
and poor health-related quality of life (HRQoL)
[8]. IPF is most common in middle-aged and
older adults [2, 9], with five times more men
than women being diagnosed with the
condition [10, 11]. Environmental factors,
such as cigarette smoking and occupational
exposures, are often cited as triggers for the
development of IPF, with recent research
indicating that a family history of fibrosis may
be the strongest risk factor [12]. However, the
exact etiology of the condition is currently
unknown [13]. Within the United Kingdom
(UK), the incidence of IPF was estimated to be
6.8 per 100,000 in 2000–2003 [14]. Global
estimates suggest an incidence of 14–43 per
100,000 [15], resulting in approximately
5 million sufferers worldwide [16], a burden
which, it is suggested, will continue to increase
[17].
IPF progression is associated with
unpredictable acute deteriorations in
respiratory function which are not associated
with any identifiable cause such as infection,
pulmonary embolism, or heart failure [18].
These episodes are termed acute exacerbations
of IPF (AE-IPF) [19, 20] and frequently result in
premature death. Mortality rate in the year
following an AE-IPF is reported to be as high as
80% [13]. The American Thoracic Society (ATS)
and European Respiratory Society (ERS) working
groups have provided diagnostic criteria and
guidelines for identifying possible AE-IPF.
Despite the terminology and criteria proposed
[2], guidance on the real-world diagnosis and
treatment of AE-IPF is largely absent from IPF
guidelines. For example, AE-IPF was absent from
the 2000 ATS/ERS international consensus
statement [2]. AE-IPF was mentioned, but not
defined nor discussed, in the 2002 ATS/ERS
international multidisciplinary consensus
statement [21], and only briefly discussed
within the 2011 ATS/ERS/Japanese Respiratory
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Society/Latin American Thoracic Association
statement [22].
There are a number of important barriers
impeding the management and treatment of
patients with AE-IPF. Despite the 2007
guidelines outlined by Collard et al. [23], there
remains a lack of consensus in defining AE-IPF,
especially relating to excluding, or
understanding, the role of infection in the
pathogenesis of the condition. In the absence
of an agreed definition, there is a lack of clear
guidelines for diagnosing and treating AE-IPF
[24].
Consensus methods such as the Delphi
technique are widely used and accepted for
medical and health service research [25–30]. For
example, the Delphi technique has recently
been used in the development of international
clinical practice statements for the treatment of
neuropsychiatric conditions associated with
epilepsy [31] and cystic fibrosis pulmonary
guidelines [32]. This specific technique is often
used in circumstances when there are gaps or
contradictions in knowledge [25].
The primary objective of this study was to
use the Delphi technique to develop a
consensus statement for the definition,
diagnosis, and treatment of AE-IPF to guide
clinicians in efficient diagnosis and treatment.
METHODS
A structured literature review was conducted
using Medline, PsycINFO, and EMBASE with a
supplemental search of grey literature, to
generate published materials that could
contribute an initial list of statements to enter
the Delphi process. The review focused on three
specific areas: current opinion on the definition
and diagnosis of AE-IPF; consensus or
agreement on the treatment of patients with
AE-IPF; and current treatment options for
patients with AE-IPF. The search specifically
targeted English language articles published
between 2003 and October 2013 using search
terms that were reviewed and agreed with
clinicians participating in the Delphi process
(Table 1).
Following completion of the literature review,
a panel of ten experts was invited to participate
in an online forum. These experts were all
practicing clinicians with experience in treating
patients with IPF. The purpose of the online
forum was to explore the results from the
literature review and discuss additional themes
that might be appropriate for inclusion in a
consensus statement. Discussion topics
included: definitions of AE-IPF proposed in the
literature review, diagnostic criteria relevant for
AE-IPF, and considerations influencing
treatment decisions. Seven of the ten
participated in the forum, during which initial
statements were formulated and reviewed by the
panel chairperson to confirm clinical accuracy
before the first round of the Delphi technique.
The Delphi technique was executed largely
in accordance with the methods described by
Jones and Hunter [25]. Delphi Panel
participants (ten specialist respiratory
clinicians with experience in treating patients
Table 1 Literature review search strategy
Search terms
Idiopathic pulmonary ﬁbrosis OR IPF OR pulmonary
ﬁbrosis OR interstitial lung disease(s) OR idiopathic
interstitial pneumonia OR IIP OR cryptogenic
ﬁbrosing alveolitis OR usual Interstitial pneumonia
OR UIP
AND acute OR exacerbation(s)
AND guideline(s) OR consensus OR statement(s) OR
recommendation(s) OR best practice
AND treatment(s)
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with IPF) were identified by the panel
chairperson, based on common adopted
criteria [33] and independently recruited to
participate. An iterative approach was
employed where sequential surveys were
presented to the panel of experts to gain
consensus [34]. Participants reviewed and
commented on the statements in isolation and
all responses were anonymized, ensuring each
participant provided their own opinion without
influence [25]. For each statement, all ten
participants were asked to judge whether the
statement was clear (‘yes’ or ‘no’), whether they
believed that the statement should be included
(1 = ‘definitely not include’ to 9 = ‘definitely
include’), and finally to provide any comments,
in the form of free text, that might help clarify
the meaning of the statement (Fig. 1).
Using the criteria in Table 2, all statements
were analyzed to determine whether the
statement should be considered for inclusion,
with or without modification [35]. All ten
clinicians participated in round one and two,
and nine clinicians participated in round three.
Following the first round of the Delphi
technique, participants were presented with
the panel results. Where statements remained
unmodified, participants were shown their
individual ratings and the group ratings. This
included the percentage of the group that
agreed the statement was clear, median rating
for inclusion, percentage of the group who rated
the statement as ‘definitely include’, and
combined comments. Where a statement was
modified, participants were shown the same
information and asked to re-rate the revised
Fig. 1 Overview of consensus statement development and the Delphi technique. AEs acute exacerbations, IPF idiopathic
pulmonary ﬁbrosis
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statements. Deleted statements were not
presented to the panel in subsequent rounds.
Non-responders were sent weekly follow-up
email reminders to complete the online survey.
Data collection for all three rounds took place
over 5 months; however, data collection per
round lasted no longer than 4 weeks. Consistent
thresholds were maintained throughout each
round [35].
A diagrammatic representation of the entire
research process is presented in Fig. 1. All
research was designed to comply with the
British Healthcare Business Intelligence
Association (BHBIA) Legal and Ethical
Framework.
RESULTS
The literature search strategy (Fig. 2) identified
16 articles for inclusion in the literature review
[1, 15, 21–23, 36–46] including, 8 original
articles, 5 review articles on IPF management,
outcomes, diagnosis or prognosis, and 3
guidelines/consensus statement articles.
Findings from the literature review indicated
contradictory opinions regarding AE-IPF
definition and diagnosis, with some suggesting
the Collard [41] definition excluded many
patients who would be treated for an acute
exacerbation in routine clinical practice. There
was also little consensus or agreement on AE-IPF
treatment, with studies suggesting a number of
pharmacological treatments such as
corticosteroids [15, 23, 38, 40, 41, 43, 46],
immunosuppressants [38, 40, 41, 45],
combinations of immunosuppressants and
anti-fibrotic drugs [39, 40], antibiotics [38],
tyrosine kinase receptor inhibitor [44],
anti-coagulation therapy [23, 40], and
non-pharmacological treatments such as
polymyxin B-immobilized fiber column
treatment [36, 37, 40], mechanical ventilation
[38, 40, 46], and lung transplantation [40].
Seven participants took part in the online
forum with five of these also participating in a
face-to-face meeting to discuss clinically
meaningful ways to define AE-IPF and its
treatment. Following the online forum and
face-to-face meeting, 65 statements were
developed. These addressed AE-IPF definition,
AE-IPF acute treatment including supportive
measures, anti-microbials, immunosuppressants,
anti-coagulants, anti-fibrotic therapy, escalation,
Table 2 Delphi technique statement inclusion key
Statement
result
Threshold applied
Deﬁnitely
include
1. C80% of panel rate statement as = 9
OR
2. Median rating of C8
Maybe
include
1. C70% of panel rate statement as = 9
OR
2. Median rating of C7
Deﬁnitely
exclude
1.\70% of panel rate statement as = 9
AND
100% panel understand statement
OR
2. Median B6
AND
100% panel understand statement
(suggesting that low scores are not due to
lack of understanding of item)
Review 1. Major revisions suggested
OR
2.\70% of panel rate statement as = 9
AND
\100% panel understand statement
(suggesting that low scores are not due to
lack of understanding of item)
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transplant management, and long-term
management including discharge planning and
preventative therapies.
Ten senior respiratory consultants
participated in the initial and second rounds
of the Delphi survey. Nine participated in the
third and final rounds. All participants were
experienced in treating patients with AE-IPF
(Table 3).
Following round 1 review of the 65
statements, 10 were deleted, 29 revised, and
26 remained unmodified (Table 4). AE-IPF
definition statements were revised such that
infection was excluded ‘as far as possible’ rather
than ‘per routine clinical practice’. As such, an
anti-infective treatment path statement was
also revised to include a footnote that negative
diagnosis is never completely certain.
Additionally, references to specific doses of
treatments were removed. All deleted
statements in round one were excluded due to
low ratings.
Fifty-five remaining statements were
reviewed in round 2, 11 of which were
deleted, 32 unmodified, and 12 revised based
on participants’ comments. Following round
two, statements were revised to either enhance
clarity or exclude reference to specific
potentially preventive therapies, such as
co-trimoxazole, nintedanib, and anti-fibrotic
therapy. Additionally, examples of supportive
measures were removed from statements as they
were not considered exhaustive. Two treatment
statements were removed relating to oxygen
supportive measures as it was agreed there is
current lack of evidence to guide oxygen
therapy. Of the remaining 44 statements in
round 3, 1 was revised and 5 deleted resulting in
39 final statements (Table 4). Statements were
deleted from oxygen supportive measures,
treatment paths, anti-reflux therapy, and
anti-infective topics due to their low ratings.
The final consensus statement is presented in
Table 5. The single statement revision in round
three was a grammatical change to enhance
clarity. Statements were deleted at each round
either due to low ratings or conceptual
overlapping with other statements.
Fig. 2 Literature search strategy. AE-IPF acute exacerbations of idiopathic pulmonary ﬁbrosis
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Table 3 Delphi technique panel member demographic characteristics
Demographic characteristics Round 1 (N5 10) Round 2 (N5 10) Round 3 (N5 9)
Gender, n (%)
Male 5 (50%) 5 (50%) 4 (44%)
Female 5 (50%) 5 (50%) 5 (56%)
Age (years), mean (SD) 44.9 (5.1) 44.9 (5.1) 44.6 (5.4)
Time as a respiratory specialist (years), mean (SD) 12.6 (3.8) 12.6 (3.8) 12.8 (4.0)
Patients with IPF treated in the last 12 months
Mean (SD) 156 (112.7) 151 (118.3) 157 (124.9)
Min–Max (25–300) (25–350) (25–350)
IPF idiopathic pulmonary ﬁbrosis, SD standard deviation
Table 4 Results of Delphi review of statements
Statement result Round 1 Round 2 Round 3
Number of statements, N 65 55 44
Deﬁnitely include, n 36 35 36
Median rating of statements 8.76 8.82 8.89
Percentage of panel rating statements C9 62% 73% 83%
Percentage of panel understanding statement 94% 98% 99%
Maybe include, n 7 9 3
Median rating of statements 7.29 7.22 7.00
Percentage of panel rating statements C9 37% 20% 15%
Percentage of panel understanding statement 86% 96% 100%
Deﬁnitely exclude, n 4 5 3
Median rating of statements 5.38 5.90 6.00
Percentage of panel rating statements C9 25% 14% 7%
Percentage of panel understanding statement 100% 100% 100%
Review, n 18 6 2
Median rating of statements 5.33 6.00 6.00
Percentage of panel rating statements C9 24% 10% 22
Percentage of panel understanding statement 83% 83% 84
Final number of statements, N 55 44 39
Adv Ther (2015) 32:929–943 935
Table 5 Final AE-IPF consensus statement
AE-IPF deﬁnition
Development or worsening of breathlessness within the preceding 30 days that is otherwise unexplained
New diffuse chest inﬁltrates on chest X-ray and/r HRCT that are otherwise unexplained
Exclusion of infection, in as far as possible, according to routine clinical practice and standard local practice, through
microbiological studies and viral studies
Exclusion of alternative causes as per routine clinical practice including left heart failure, PE, and identiﬁable causes of
acute lung injury
AE-IPF treatment path
Supportive measures should be provided to increase patient comfort
AE-IPF treatment path
Acute treatment
Supportive measure: Oxygen
Oxygen should be supplied to correct hypoxia and improve dyspnea
It is advised to titrate SpO2 to[88%
High-ﬂow oxygen delivery mechanism, e.g., OptiﬂowTM (Fisher & Paykel Healthcare), may be required
A test dose of a benzodiazepine (generally lorazepam) may be prescribed followed by monitoring of SaO2 to avoid
respiratory depression
If a benzodiazepine is beneﬁcial, dose should be titrated accordingly to manage symptoms
Opiates may be prescribed in combination with a benzodiazepine, or alone if a benzodiazepine test dose is not tolerated
Supportive measure: psychological and spiritual support
Psychological and/or spiritual support should be offered to all patients as appropriate
Anti-infectivesa
A broad spectrum respiratory antibiotic should be prescribed as determined by clinical judgment in conjunction with
local guidelines
If a patient has recently been admitted as an inpatient they should additionally be covered for hospital acquired infection
Anti-virals should not be prescribed routinely but only in cases of strong clinical suspicion and in accordance with local
guidelines
Immunosuppressants
Corticosteroids should be considered in all patients unless speciﬁcally contra-indicated
Long-term corticosteroid dosing should be determined based on the individual patient
Cyclophosphamide/azathioprine/MMF should not be prescribed
The use of biologics, e.g., rituximab, is not recommended
Anti-coagulants
LMW heparin and/or anticoagulants should be initiated prophylactically to prevent DVT according to standard hospital
policy, unless patients are already receiving anticoagulation therapy
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Table 5 continued
Anti-ﬁbrotic therapy
If patients are already receiving anti-ﬁbrotic therapy then this should be continued
Patients should not be initiated on anti-ﬁbrotic therapy in the setting of an acute exacerbation
Escalation
Intubation and mechanical ventilation are not part of standard care
Where possible the decision not to intubate or initiate mechanical ventilation should be discussed with patients at an
early stage after IPF diagnosis
CPAP can provide a helpful supportive measure
End of life care should be discussed and agreed with patients and their families
Transplant
If patients are already on the transplant waiting list then the transplant unit should be informed
If patients recover from AE-IPF review suitability for transplant referral, ideally at an early follow-up appointment in the
clinic
Long-term management
Appropriate long-term management is essential following AE-IPF by a clinician with specialist expertise in IPF
management
As part of long-term management a review should assess the need for transplant referral
As part of long-term management a review should assess the need for anti-ﬁbrotic treatment
As part of long-term management a review should assess the suitability for inclusion in clinical trials
As part of long-term management a review by a respiratory physiotherapist should assess the need for pulmonary
rehabilitation
Appropriate supportive and palliative care mechanisms should be put in place
Discharge planning
Discharge planning should ensure adequate home oxygen is in place prior to discharge if required
Discharge planning should ensure an early post-discharge review at an ILD clinic is in place (within 4–6 weeks)
An appropriate discharge letter should be provided
Preventative therapies
There is no clear evidence to provide recommendations for preventative therapies at present
Additional information
Note that this is an opinion-led standard of care and that there is an absence of an evidence base
AE-IPF acute exacerbations of idiopathic pulmonary ﬁbrosis, CPAP continuous positive airway pressure, DVT deep venous
thrombosis, HRCT high-resolution computed tomography, ILD interstitial lung disease, LMW low molecular weight,
MMF mycophenolate mofetil, PE pulmonary embolism, SpO2 peripheral oxygen saturation
a Negative diagnosis is never completely certain
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DISCUSSION
The aim of this study was to develop a
consensus statement for AE-IPF definition,
diagnosis, and treatment to guide clinicians in
efficient diagnosis and treatment. The literature
review, online discussion, and Delphi technique
generated 65 initial statements. Following 3
rounds of review, 39 statements were included
in the final consensus statements.
The aim of a consensus statement is to reach
an acceptable level of agreement between panel
members on a particular issue to achieve
convergence of opinion. This specific
methodology, as opposed to alternative
consensus approaches such as nominal group
technique [47] or social judgment analysis [48],
was considered a more appropriate approach
because of lack of clinical guidelines currently
in the literature. As a consensus method, the
Delphi technique has advantages in that it can
accommodate knowledge gathering from a
number of clinical experts in various
geographical locations, reducing potential
participant burden by omitting travel. The
Delphi technique has been applied to achieve
a variety of objectives: determining a range of
possible program alternatives, exploring
underlying assumptions leading to different
judgments within a respondent panel,
correlating informed judgments on a topic
spanning a wide range of disciplines,
educating the respondent panel to diverse and
interrelated topics, and, importantly,
generating consensus [33]. This method is
useful in the absence of extensive
research-based evidence, when the
development of guidelines must be based on
the experience and opinions of clinicians [49].
Additionally, the Delphi technique offers the
advantage of numerically combining
participant responses, resulting in a more
reliable statement than estimates from a single
person [49]. Moreover, this approach allows the
iterative exchange of information between
individuals under controlled conditions,
limiting the potentially detrimental effects of
interaction [49].
Following each round of review, changes and
deletions were made to statements that
highlight some of the challenging decisions in
this area. Revisions were made to AE-IPF
definition statements to clarify that exclusion
of infection should be ‘as far as possible’ rather
than ‘as per routine clinical practice’. This
change was made to reflect the challenges
inherent in disproving any contribution of
infection in the etiology of at least some cases
of AE-IPF and the difficulties frequently
encountered in clinical practice of performing
intrusive investigations such as bronchoscopy
on often critically unwell patients.
Reference to specific doses of drugs was
removed from statements, as there is no
empirical evidence to support a specific dosing
regimen, for example, for corticosteroids, in
AE-IPF. Additionally, statements were revised to
exclude reference to specific preventative
therapies as, at the time of conducting this
research, there was no clear evidence to support
any such recommendations. Despite the lack of
evidence, preventative therapies that were
routinely advised by the panel are influenza
and pneumococcal vaccination, and prompt
treatment of lower respiratory tract infections.
The role of oxygen therapy in AE-IPF
generated considerable discussion. Clinicians
believed that the British Thoracic Society (BTS)
oxygen guidelines [50] are unhelpful in
individuals with IPF because they are based
heavily on evidence derived from studies of
patients with chronic obstructive pulmonary
disease (COPD); a disease which is characterized
by an altogether different pathophysiology. The
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BTS guidelines advise titrating oxygen therapy
by measuring arterial blood gases. The panel
considered that it is inappropriate to perform
repeated arterial sampling on ill patients
suffering from an AE-IPF because unlike COPD
these patients typically develop hypoxic rather
than hypercapnic respiratory failure, so that
oxygen saturations provide sufficient
information.
Most statements relating to psychological
support, escalation, anti-fibrotic therapy,
transplant, long-term management, and
discharge planning were retained with only
minor wording modifications to enhance
clarity of statements. Three statements were
included relating to benzodiazepines and
opiates; minor word modifications were made
to these statements following round two to refer
to benzodiazepine rather than lorazepam, and
all clinicians agreed on the importance of
benzodiazepine and opiates as anxiolytic
supportive measures. Statements
recommended that benzodiazepine may be
prescribed alongside monitoring of oxygen
saturation to avoid respiratory depression, and
benzodiazepines and opiates may be used in
combination, or alone, if well tolerated.
However, it should be noted that decisions to
remove and modify statements per round were
based on clinical expert opinion rather than
being evidence based.
Despite the degree of input and consensus
among clinical experts to generate these
statements, this study is not without
limitations. The literature review aimed to
stimulate discussion for the online forum and
was based on a small number of papers focusing
on AE-IPF diagnosis and management. Given
that the literature review was limited in scope
and not a systematic review, the scope was not
exhaustive. However, a specialist clinician
reviewed the literature review report,
strengthening confidence in the literature
review evidence. The online forum and Delphi
technique included a small number of specialist
clinicians from the UK, so results may not be
generalizable to other countries. However, as
the number of specialist clinicians treating
AE-IPF is small, the study sample is considered
reasonable. Nevertheless, the use of specialist
clinicians only in the UK limits the
generalizability of the study findings.
Furthermore, there are limitations to the
Delphi technique, with some authors
suggesting it does not meet the rigorous
standards of other scientific methods [51, 52].
However, given that there is limited AE-IPF
guidance, the anonymous, iterative process of
controlled feedback and clinical input achieved
by this technique was best suited to the
development of a consensus statement for
AE-IPF. Furthermore, this technique has been
successfully implemented to generate
consensus statements in other therapeutic
areas [26].
CONCLUSIONS
The final 39 consensus statements included
topics on definition of AE-IPF, approach to
diagnosis, and treatment options, specifically:
supportive measures, use of anti-microbials,
immunosuppressants, anti-coagulants,
anti-fibrotic therapy, escalation, transplant
management, and long-term management
including discharge planning. The
clinician-led consensus statement resulting
from this Delphi technique outlines
appropriate guidance for AE-IPF definition,
diagnosis, and treatment, and is intended to
direct decision making in the clinical
management of patients with AE-IPF.
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